The cAMP Specific 3′,5′ Cyclic Phosphodiesterase 4B pipeline drugs market research report outlays comprehensive information on the cAMP Specific 3′,5′ Cyclic Phosphodiesterase 4B targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses the drugs in the cAMP Specific 3′,5′ Cyclic Phosphodiesterase 4B pipeline by therapy areas, indications, stages, MoA, RoA, molecule type and the key players in the development pipeline. Buy the report here.
Smarter leaders trust GlobalData
The report also covers products from therapy areas such as Respiratory, Central Nervous System, Musculoskeletal Disorders, and Immunology which include the indications Respiratory, Asthma, Schizophrenia, Unspecified Neurologic Disorders, Psoriatic Arthritis, Plaque Psoriasis (Psoriasis Vulgaris), and Palmoplantar Pustulosis. It also reviews key players involved in cAMP Specific 3′,5′ Cyclic Phosphodiesterase 4B targeted therapeutics development with respective active and dormant or discontinued products.
The cAMP Specific 3′,5′ Cyclic Phosphodiesterase 4B pipeline targets constitutes close to seven molecules. Out of which, approximately seven molecules are developed by companies and the remaining by the universities/institutes. The molecules developed by companies in Phase III, IND/ CTA Filed, and Preclinical stages are 2, 1, and 4 respectively.
cAMP Specific 3′,5′ Cyclic Phosphodiesterase 4B overview
cAMP specific 3′,5′ cyclic phosphodiesterase 4B (PDE4B) is a member of the type IV, cyclic AMP (cAMP)-specific, cyclic nucleotide phosphodiesterase (PDE) family. PDE4B hydrolyzes the second messenger cAMP, which is a key regulator of many important physiological processes.
For a complete picture of cAMP Specific 3′,5′ Cyclic Phosphodiesterase 4B’s drug pipeline, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third-party sources.
Drug profiles featured in the report undergo periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
